Format

Send to

Choose Destination
J Thorac Oncol. 2008 Jan;3(1):94-7. doi: 10.1097/JTO.0b013e31815eb7a2.

Thymic carcinoid responds to neoadjuvant therapy with sunitinib and octreotide: a case report.

Author information

1
Division of Hematology, Oncology, and Transplantation, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA.

Abstract

Carcinoids are malignant neuroendocrine tumors consisting of a spectrum of neoplasms from low-grade typical carcinoid to high-grade small cell carcinoma. We report a case of atypical thymic carcinoid that responded to neoadjuvant therapy with octreotide and sunitinib, an oral multikinase inhibitor. After 3 weeks of treatment, tumor size significantly decreased to allow for a safe surgical resection with clear margins. We believe that further study of sunitinib and octreotide with the neoadjuvant intent of preparing tumors for resection is warranted as a strategy to improve curative management of neuroendocrine tumors.

PMID:
18166847
DOI:
10.1097/JTO.0b013e31815eb7a2
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center